Abstract
Metabolic syndrome (MetS) is a world-wide epidemic disease associated with increased morbidity and mortality. Treatment strategies include pharmacologic and non-pharmacologic methods, with varying degrees of success rate all over the world. Pharmaceutical interest in this field is growing, together with patients’ requests for supplementary (or “alternative”) treatments. The knowledge of nutraceuticals beneficial effects in subjects with the MetS could help us to better define the appropriate treatment for these subjects, in particular those with contraindications for commonly used drugs, or to achieve guidelines suggested targets. On the other side, it could be not convenient to use a nutraceutical to treat each metabolic syndrome component (i.e. from 3 to 5) in each affected subjects. Thus, this review tries to focus on widely marketed nutraceuticals with clinically demonstrated effects on more than one component of the MetS, namely omega-3 fatty acids, berberine, psyllium and other soluble fibers, cinnamon, chromium picolinate, banaba, and bitter gourd.
Keywords: Metabolic syndrome, diabetes, hypertension, dyslipidemia, nutraceuticals, insulin resistance, obesity.
Current Vascular Pharmacology
Title:Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Volume: 12 Issue: 4
Author(s): Arrigo F. Cicero, Elisa Tartagni and Sibel Ertek
Affiliation:
Keywords: Metabolic syndrome, diabetes, hypertension, dyslipidemia, nutraceuticals, insulin resistance, obesity.
Abstract: Metabolic syndrome (MetS) is a world-wide epidemic disease associated with increased morbidity and mortality. Treatment strategies include pharmacologic and non-pharmacologic methods, with varying degrees of success rate all over the world. Pharmaceutical interest in this field is growing, together with patients’ requests for supplementary (or “alternative”) treatments. The knowledge of nutraceuticals beneficial effects in subjects with the MetS could help us to better define the appropriate treatment for these subjects, in particular those with contraindications for commonly used drugs, or to achieve guidelines suggested targets. On the other side, it could be not convenient to use a nutraceutical to treat each metabolic syndrome component (i.e. from 3 to 5) in each affected subjects. Thus, this review tries to focus on widely marketed nutraceuticals with clinically demonstrated effects on more than one component of the MetS, namely omega-3 fatty acids, berberine, psyllium and other soluble fibers, cinnamon, chromium picolinate, banaba, and bitter gourd.
Export Options
About this article
Cite this article as:
Cicero F. Arrigo, Tartagni Elisa and Ertek Sibel, Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/15701611113119990120
DOI https://dx.doi.org/10.2174/15701611113119990120 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety and Efficacy of Novel Oral Anticoagulants: A Comparison to Vitamin K Antagonists
Cardiovascular & Hematological Agents in Medicinal Chemistry Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Effects of Huangkui Capsule on the Expression of SPARC in the Kidney Tissue of a Rat Model with Diabetic Nephropathy
Current Gene Therapy The Management of the Infected Diabetic Foot
Current Diabetes Reviews Editorial (Hot Topic: The New Kids on the Block: Oral Direct IIa and Xa Inhibitors Enter the Proscenium of Anticoagulation Treatment)
Current Clinical Pharmacology Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Radiopharmaceuticals Regulations: Current Scenario and the Way Forward
Applied Clinical Research, Clinical Trials and Regulatory Affairs Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis
Current Pharmaceutical Design A Cell Culture Model for the Assessment of the Chemopreventive Potential of Dietary Compounds.
Current Nutrition & Food Science Physical Exercise and Major Depressive Disorder - Where Do We Stand?
Current Psychopharmacology Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Editorial:A New Journal with an Integrated Approach in the Study of Aging and Longevity
Current Aging Science Cardiovascular Risk in Perimenopausal Women
Current Vascular Pharmacology Antioxidant Response of Osteoblasts to Doxycycline in an Inflammatory Model Induced by C-reactive Protein and Interleukin-6
Infectious Disorders - Drug Targets Statins in Aortic Disease
Current Pharmaceutical Design